ASH 2018 | Tagraxofusp for BPDCN gives encouraging results
Naveen Pemmaraju
With no approved treatment options for blastic plasmacytoid dendritic cell neoplasm (BPDCN), Naveen Pemmaraju, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, presents the results of a Phase II study (NCT02113982) testing the novel agent SL-401 (tagraxofusp). Speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA., Dr Pemmaraju discusses the breakthrough finding that CD123 is overexpressed in all these patients, and how use of the first-in-class tagraxofusp has shown high response rates in this patient population.
Related videos
An exciting era for CAR T-cell therapy
Mohamad Mohty
1:01
Metabolic profiling of the leukemia stem cell
Giovanni Martinelli
1:33
PALB2 predicts poor prognosis in AML and indicates potential targets for synthetic lethal therapies
Giovanni Martinelli
3:56
RADIUS results: midostaurin reduces relapse after ASCT in FLT3-ITD AML
Richard Thomas Maziarz
3:06
Improved understanding of CPX-351 in AML: impact of HCT & final EAP results
Tara Lin
